LPL Financial LLC Has $614,000 Stake in Castle Biosciences, Inc. (NASDAQ:CSTL)

LPL Financial LLC lessened its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) by 12.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 23,043 shares of the company’s stock after selling 3,421 shares during the period. LPL Financial LLC owned 0.08% of Castle Biosciences worth $614,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. R Squared Ltd acquired a new position in shares of Castle Biosciences during the fourth quarter valued at about $42,000. KLP Kapitalforvaltning AS acquired a new position in Castle Biosciences during the 4th quarter worth approximately $128,000. China Universal Asset Management Co. Ltd. boosted its holdings in Castle Biosciences by 11.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,939 shares of the company’s stock worth $158,000 after acquiring an additional 604 shares in the last quarter. Oak Harvest Investment Services acquired a new stake in Castle Biosciences in the fourth quarter valued at approximately $206,000. Finally, Green Alpha Advisors LLC bought a new stake in shares of Castle Biosciences during the fourth quarter valued at approximately $249,000. 92.60% of the stock is owned by institutional investors.

Castle Biosciences Stock Down 3.2 %

CSTL opened at $21.27 on Thursday. Castle Biosciences, Inc. has a fifty-two week low of $16.97 and a fifty-two week high of $35.84. The firm has a market capitalization of $613.53 million, a P/E ratio of 106.36 and a beta of 1.11. The company’s 50-day moving average is $21.29 and its 200 day moving average is $26.71. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.78 and a quick ratio of 7.64.

Insider Buying and Selling at Castle Biosciences

In related news, Director Daniel Bradbury sold 7,867 shares of the stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $28.17, for a total transaction of $221,613.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Derek J. Maetzold sold 22,639 shares of the firm’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $20.12, for a total transaction of $455,496.68. Following the sale, the insider now owns 80,465 shares of the company’s stock, valued at $1,618,955.80. This trade represents a 21.96 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 35,321 shares of company stock worth $774,644. Insiders own 7.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on CSTL shares. Robert W. Baird increased their target price on Castle Biosciences from $36.00 to $37.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. Guggenheim set a $30.00 price objective on shares of Castle Biosciences and gave the stock a “buy” rating in a report on Friday, March 28th. Finally, Stephens reiterated an “overweight” rating and set a $41.00 price objective on shares of Castle Biosciences in a report on Thursday, January 2nd. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $38.75.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.